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DOI 10.1016/j.ccr.2012.03.045SUMMARYCancer cells typically exhibit aberrant DNA methylation patterns that can drive malignant transformation.
Whether cancer cells are dependent on these abnormal epigenetic modifications remains elusive. We
used experimental and bioinformatic approaches to unveil genomic regions that require DNA methylation
for survival of cancer cells. First, we surveyed the residual DNAmethylation profiles in cancer cells with highly
impaired DNA methyltransferases. Then, we clustered these profiles according to their DNA methylation
status in primary normal and tumor tissues. Finally, we used gene expression meta-analysis to identify
regions that are dependent on DNAmethylation-mediated gene silencing. We further showed experimentally
that these genes must be silenced by DNA methylation for cancer cell survival, suggesting these are key
epigenetic events associated with tumorigenesis.INTRODUCTION
During tumorigenesis cancer cells acquire, through a multistep
process, a new set of properties that allows them to overcome
physiological homeostasis. These properties include unlimited
proliferation potential, self-sufficiency in growth signals, resis-
tance to antiproliferative and apoptotic signals and immune
system evasion, among others (Hanahan and Weinberg, 2000,
2011). These alterations, on the other hand, contribute to a
process known as the stress phenotype of cancer (Luo et al.,
2009), which includes DNA damage/replication stress, proteo-
toxic stress, mitotic stress, metabolic stress, and oxidative
stress.
To survive the tumorigenic process, a cancer cell undergoes
several modifications to its genomic circuitry, such as activating
mutations in oncogenes and aberrant activation of nononco-
genic pathways. These adaptations lead to oncogene addiction
(Weinstein, 2002) and nononcogene addiction (Solimini et al.,Significance
Epigenetic modifications are potentially reversible, making them
cannot survive in the absence of aberrant DNA methylation of
cells more susceptible to epigenetic therapy. We also found th
is necessary for somatic cell survival, suggesting a physiolog
regions in somatic tissues. Moreover, by defining the promoter
in culture, we found several genes that acquire de novo DNAm
interpretation of epigenetic results obtained from cell culture e2007), respectively. Because of this aberrant circuitry, cancer
cells become hypersensitive to the effects of classic tumor
suppressor genes (TSGs) (Luo et al., 2009; Weinstein, 2002)
and, potentially, to genes that can inhibit the nononcogenic
signaling pathways that cancer cells rely on to survive.
Changes in the cancer cell transcriptome can be driven by
genetic and epigenetic alterations (Baylin and Ohm, 2006; Jones
and Baylin, 2007). DNA methylation is an epigenetic process
that can heritably change gene expression without altering the
DNA sequence. In normal somatic cells, most DNA methylation
occurs at CpG dinucleotides within CpG poor sequences,
whereas CpG-rich sequences, also known as CpG islands, are
usually unmethylated (Sharma et al., 2010). DNA methylation is
a vital mechanism of epigenetic gene silencing, playing key
roles in X chromosome inactivation, genomic imprinting, embry-
onic development, silencing of repetitive elements and germ
cell-specific genes, differentiation, and maintenance of pluripo-
tency (De Carvalho et al., 2010; Meissner, 2010; Robertson,good ‘‘druggable’’ targets. Here, we show that cancer cells
specific promoter regions. This process may render cancer
at physiological DNAmethylation of germline-specific genes
ical dependence on continuous DNA methylation of these
regions that must be methylated in order for cells to survive
ethylation in cell lines, highlighting the importance of careful
xperiments.
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Figure 1. Clustering of DNMT-Deficient Cells Identifies Three Classes of Putative Driver Genes Marked by DNA Methylation
(A) One-dimensional hierarchical clustering using Euclidean distance and average linkage was performed with the 24,000 Infinium DNA methylation probes
located outside of repeats or known SNPs in HCT116 wild-type, DKO8, and DKO1 cell lines. Each row represents a probe; each column represents a sample. The
b value (level of DNA methylation) for each probe is represented with a color scale as shown in the key.
(B) k Means (K = 4) clustering of the 566 InfiniumDNAmethylation probes that maintain DNAmethylation in DKO1 sample (a b value of at least 0.6 and a difference
between HCT116 and DKO1 smaller than 0.2) in (A) for 10 TCGA samples (n = 4 normal colon and n = 6 primary colon adenocarcinoma).
(C) Heat map of 566 Infinium DNA methylation probes in 32 normal tissues retaining the probe order from (B). Primary normal bladder (n = 4), sperm (n = 1), and
primary normal TCGA kidney (n = 15), lung (n = 4), and ovary (n = 8). WGA DNA was used as a negative control for DNA methylation.
(D) Bisulfite-sequencing validation of Infinium DNAmethylation data from two regions (LDHAL6B and ADAM2) from the somatic-specific DNAmethylation cluster
and two regions (ARMCX1 and MEOX2) from the cancer-specific DNA methylation cluster. Arrow indicates the position of the Infinium probe. Empty and filled
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DNA Methylation Drivers2005). Besides these physiological roles, deregulated DNA
methylation can also be amajor driver of pathological conditions,
including neurological and autoimmune diseases, as well as
cancer (Kelly et al., 2010; Portela and Esteller, 2010; Taberlay
and Jones, 2011). During tumorigenesis, global DNAmethylation
patterns change, resulting in hypomethylation of non-CpG
islands and hypermethylation of CpG islands (Sharma et al.,
2010). DNA hypermethylation has been shown to result in
abnormal silencing of several TSGs in most types of cancer
(Jones and Baylin, 2002, 2007).
Recently, several efforts to examine the cancer methylome,
utilizing genome-wide techniques, have revealed that a large
number of genes exhibit aberrant DNA methylation profiles in
cancer (Figueroa et al., 2010; Irizarry et al., 2009). These changes
can be used to stratify subtypes of cancers (Figueroa et al., 2010;
Noushmehr et al., 2010) and to predict cancer outcomes (Portela
and Esteller, 2010), among other uses. Distinguishing which
genes play key ‘‘driver’’ roles via DNA methylation-mediated
gene silencing in cancer initiation, progression, andmaintenance
and those genes that are only ‘‘passengers’’ in the tumorigenic
process would be extremely useful in developing more targeted
epigenetic therapies (Kelly et al., 2010). However, making this
distinction has proven extremely difficult due to the large number
of differentially DNA-methylated genes in human cancers (Kalari
and Pfeifer, 2010).
We, and others, have suggested that cancer cells may
become addicted to an aberrant epigenetic landscape, espe-
cially with respect to DNA methylation (Baylin and Ohm, 2006;
Kelly et al., 2010). However, as of yet, and to our knowledge,
there is no direct evidence for such an addiction. Furthermore,
mining the thousands of genomic regions that are de novo
DNA methylated in cancer and identifying those required for
cancer cell survival have proven extremely challenging (Kalari
and Pfeifer, 2010). Here, we describe an approach to identify
driver epigenetic events associated with cancer cell survival.
Our findings pave the way for new generations of epigenetic
therapies, which target the genes cancer cells rely on being
silenced by DNA methylation in order to survive.
RESULTS
Identification of the Minimum DNA Methylation Profile
Required for Cancer Cell Survival
We hypothesized that cancer cells depend on DNA methylation
of a few key regions for survival and that these regions would
preferentially maintain methylation when artificially reducing
global DNA methylation. To test this hypothesis, we profiled
HCT116 colon cancer cells and HCT116 cells with a genetic
disruption of DNMT3B and DNMT1 (DKO) (Rhee et al., 2002).
This genetic disruption led to a complete knockout of DNMT3B
and a truncated DNMT1 transcript, expressed at very low levels
(Egger et al., 2006; Rhee et al., 2002; Spada et al., 2007). For this
study we used two DKO subclones, DKO8 and DKO1, whichcircles denote unmethylated and methylated CpG sites, respectively. Each hor
represents the mean DNA methylation score of each region, and the number in
Infinium CpG site.
See also Figure S1 and Table S1.retain approximately 45% and 5% of the HCT116 wild-type
global DNA methylation levels, respectively (Rhee et al., 2002;
Sharma et al., 2011). It is important to note that a further reduc-
tion of DNMT1 levels, by RNAi, in cells with a genetic disruption
of DNMT1 results in demethylation and a massive reduction
of cell viability and immediate induction of cell death (Spada
et al., 2007), suggesting that DNA methylation is required for
cancer cell survival.
We profiled promoter DNA methylation of HCT116, DKO8,
and DKO1 cell lines using the Illumina Infinium platform
(HumanMethylation27) and observed a reduction in global DNA
methylation levels in DKO8 cells compared to HCT116 wild-
type cells and an even greater reduction in DKO1 cells (Fig-
ure 1A), consistent with previous data (Rhee et al., 2002; Sharma
et al., 2011). Surprisingly, we found a collection of 566 CpG sites,
spanning 490 genes that despite the strong impairment in DNA
methyltransferase activity, still retained a high level of DNA
methylation in DKO1 cells, with a b value higher than 0.6 (see
Table S1 available online for gene/probe list). These regions
were also highly methylated in HCT116 and DKO8 cells, and
none showed a difference in their b values greater than 0.2
among the three cell lines.
Next, we sought to identify whether there was a cancer-
specific DNAmethylation profile at these regions thatmaintained
DNA methylation even in DKO1 cells, which would potentially
include important putative targets for epigenetic therapy. To
accomplish this, we first compared the DNA methylation levels
of the 566 CpG sites that retained DNA methylation in DKO1
cells to the DNAmethylation profile of 6 primary colon adenocar-
cinoma tissue samples and 4 normal colon tissue samples
obtained from The Cancer Genome Atlas (TCGA) database.
Using k means clustering, we identified 92 CpG sites, spanning
77 genes that were unmethylated in normal colon and became
hypermethylated in colon adenocarcinoma (Figure 1B; Table
S1), consistent with a cancer-specific methylation profile.
We further compared these data to DNA methylation data of
several normal tissues including sperm, bladder, kidney, lung,
and ovary, which allowed us to identify clusters of gene regions
highly enriched for somatic tissue-specific DNA methylation.
Such genes were methylated in the somatic tissues analyzed
and unmethylated in germ cells. This somatic tissue-specific
cluster comprised 99 CpG sites, spanning 83 genes (Figure 1C;
Table S1). Furthermore, we also identified genes that exhibit cell
culture-specific DNA methylation, such that these regions are
methylated in all cell lines analyzed but unmethylated in primary
tissues (Figure 1C; Table S1). This cell culture-specific cluster
comprised 29 CpG sites, spanning 25 genes. We focused
only on these three groups because of their differential DNA
methylation profiles. We speculate that the remaining 346 CpG
sites might be regions that are more prone to methylation,
remaining a good target for residual DNA methylation activity
without functional relevance or, alternatively, may have a
tissue-specific expression profile, being unmethylated only inizontal row represents one sequenced DNA clone. The number on the right
the parentheses represents the mean DNA methylation score of the specific
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Genome Amplified (WGA) DNA served as a negative control (Fig-
ure 1C) to confirm that the regions identified as being methylated
in DKO1 cells were not false positives due to technical problems
with the specific Infinium probes.
The distribution of probes, relative to transcription start sites
(TSSs), in the cancer-specific and somatic tissue-specific
clusters was found to be very similar to the distribution of the
array itself, whereas the distribution in the cell culture-specific
cluster tended to be slightly more concentrated at the TSS
(Figure S1A). However, it should be noted that there was no
association between distance to TSS and methylation cluster
(somatic, cancer, cell line) as assessed by one-way ANOVA
(p > 0.05).
We selected genomic regions from each cluster to validate
the Infinium-based DNA methylation data using bisulfite
sequencing. All of the sequences analyzed showed high levels
of DNA methylation in HCT116 wild-type and DKO1 cells (Fig-
ure 1D), with the CpG site surveyed by the Infinium platform
presenting a maximum difference between their b values of
0.17 in DKO1 when compared to HCT116 wild-type. These
results demonstrate that even though DKO cells are globally
DNA hypomethylated (Rhee et al., 2002; Sharma et al., 2011),
the residual DNA methylation is focal and site specific, support-
ing the hypothesis that there is a functional role for some of the
retained DNA methylation.
To further demonstrate the importance of the DNAmethylation
that is retained in the three identified clusters, we treated DKO1
cells with 1 mM of 5-Aza-20-deoxycytidine or PBS for 24 hr. After
treatment, we allowed at least two population doublings (5 days)
for demethylation to occur and then analyzed changes in the
DNA methylation profile by the Illumina Infinium array. As ex-
pected, most of the regions in the three previously identified
clusters were resistant to demethylation, with only eight regions
from the somatic cluster, five regions from the cancer cluster,
and one region from the cell culture cluster presenting a differ-
ence in the b value greater than 0.2 (Figure S1B). These regions
we considered false positives and excluded them from subse-
quent analysis.
Residual Methylation in DKO1 Cannot Be Explained
by an Inherent Susceptibility to DNA Methylation
Our working hypothesis is that the artificial impairment of DNA
methyltransferase machinery in DKO1 cells will induce a strong
selective pressure for any remaining DNA methylation to be
maintained at the regions necessary for cancer cell survival. An
equally plausible hypothesis is that the residual methylation
reflects an inherent tendency for some genes to remain methyl-
ated. Indeed, previous studies suggest that certain genomic
regions are more prone to DNA methylation (Este´cio et al.,
2010; Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter
et al., 2007). Therefore, these regions may remain better targets
for residual DNA methylation activity. To directly test this
alternative hypothesis, we used two known approaches to
predict whether a gene is more prone to DNA methyltransferase
activity in cancer cells: one based on its chromatin structure
(Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter
et al., 2007), and another based on its genomic architecture
(Este´cio et al., 2010).658 Cancer Cell 21, 655–667, May 15, 2012 ª2012 Elsevier Inc.Genes marked by H3K27me3 in embryonic stem cells (ESCs)
are known to be predisposed to DNA methylation in cancer cells
(Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al.,
2007). Indeed, we found that the H3K27me3 status in ESCs can
accurately predict the methylation levels in the wild-type
HCT116 cells (Figure 2A). Then, we tested whether methyla-
tion-prone regions (H3K27me3 positive in ESCs) would preferen-
tially retain methylation in DKO1 cells, compared to HCT116
cells. If this hypothesis was correct, we should observe an
enrichment of methylation-prone genes in the cohort of genes
that is methylated in DKO1 cells because they would be better
targets for residual DNA methyltransferase activity. Yet, there
was no such enrichment (Figure 2B). Rather, weobserved a slight
decrease in the proportion of methylation-prone genes that
retain methylation in DKO1 cells. These data suggest that genes
found to retain DNA methylation in DKO1 cells are not simply
predisposed to DNA methylation in cancer cells.
To further test this hypothesis, we performed a similar analysis
using a previously published algorithm to predict whether
a genomic region is prone, intermediate, or resistant to DNA
methylation in cancer cells, based on its genomic architecture
(Este´cio et al., 2010). In our test this algorithm accurately pre-
dicted methylation levels in HCT116 cells (Figure 2C). Similar
to the previous analysis, if the genes that maintain methylation
in DKO1 cells were simply more prone to DNAmethyltransferase
activity, one would expect an enrichment of methylation-prone
genes in the pool of genes that retainsmethylation in DKO1 cells.
Again, we could not find such enrichment (Figure 2D).
Taken together, these data suggest that the targets of residual
DNA methylation in DKO1 cells are not dictated by an inherent
predisposition to DNAmethylation based on either the chromatin
structure or the genomic architecture. These findings further
support our original hypothesis that these loci retain methylation
due to a functional selection pressure.
Validation of the Findings in Other Types of Cancer
and Association with Gene Expression
We next validated our findings in a larger test set of colon adeno-
carcinoma and normal colon samples. Using DNA methylation
data available from TCGA, we observed a significant increase
in DNA methylation in the majority of the CpG sites identified
with cancer-specific DNA methylation in 168 primary colon
adenocarcinoma samples relative to 16 normal colon samples
(Figure 3A;Wilcoxon rank sum test followed by a FDR correction,
p < 0.05). We next extended our findings to determine whether
this cancer-specific DNAmethylation profile was unique to colon
adenocarcinoma or if it could also be observed in other tumor
types. Using DNA methylation data available from TCGA, we
analyzed DNA methylation from 19 lung adenocarcinoma
samples against 4 normal samples. Again, the same pattern
emerged, where the identified CpG sites presented an overall
significant gain of DNA methylation in the tumor samples (Fig-
ure 3C; Wilcoxon rank sum test followed by a FDR correction,
p < 0.05). Indeed, most of the genes statistically determined to
be hypermethylated in lung adenocarcinoma were also hyper-
methylated in colon adenocarcinoma (Figure 3E). These data
indicate that the CpG sites we identified as cancer specific are
frequently hypermethylated in other types of human cancer
relative to the normal cell counterparts, suggesting that these
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Figure 2. Residual Methylation in DKO1 Is Not Caused by an Inherent Susceptibility to DNA Methylation
(A) Validation of H3K27me3 status in ESCs as a predictive method for DNAmethylation in HCT116 cells. Methylation status of27,000 CpG sites was determined
by Infinium. A t test with Mann-Whitney U posttest was performed. Data represent the mean ± SEM.
(B) Frequency of probes marked by H3K27me3 in ESCs in the cohort of DNA-methylated probes (b value >0.6) in HCT116, DKO8, and DKO1 cells.
(C) Validation of the predictive method based on genomic architecture (Este´cio et al., 2010) in HCT116 cells. Methylation status of 27,000 CpG sites was
determined by Infinium. One-way ANOVA with Kruskal-Wallis test as performed. Data represent the mean ± SEM.
(D) Frequency of methylation-prone genes in the cohort of DNA-methylated genes (b value >0.6) in HCT116, DKO8, and DKO1 cells.
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such as cell survival.
Because DNA methylation of CpG islands located in promoter
regions is well known to be correlated with gene silencing (Cedar
and Bergman, 2009; Jones and Baylin, 2007; Portela and Estel-
ler, 2010), we investigated the expression state of the genes
identified using independent data sets. We selected two micro-
array data sets from the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/): colon adenocarcinoma
against normal colon (GSE 8671) (Sabates-Bellver et al., 2007);
and lung adenocarcinoma against normal lung (GSE7670)
(Su et al., 2007).
We found an inverse correlation between DNA methylation
and gene expression when we analyzed the gene expression
data of 32 normal colon samples and 25 colon tumor samples.
The majority of the genes subject to cancer-specific DNA
methylation displayed decreased gene expression in colon
cancer samples compared to normal colon (Figure 3B; t test
followed by a FDR correction, p < 0.05). We also observed
that some genes showed a similarly low level of expression
in both samples, probably due to an epigenetic switch in the
silencing mechanism where the gene was already silenced in
the normal sample by another epigenetic mechanism and
became de novo DNA methylated in cancer (Gal-Yam et al.,
2008).
Moreover, we found a similar gene expression pattern in lung
adenocarcinoma, where most of the cancer-specific DNAmethylation genes displayed decreased gene expression in the
tumor when compared to the correspondent normal tissue
(Figure 3D; t test followed by a FDR correction, p < 0.05). Again,
most of the genes statistically repressed in lung adenocarci-
noma were also repressed in colon adenocarcinoma (Figure 3F).
These data further suggest that there is a functional relevance of
identified DNA methylation.
Altogether, by combining gene expression with DNA methyla-
tion data, we identified regions that are candidates for DNA
methylation-mediated gene silencing. Moreover, the gene
expression data corroborate our cluster analysis by using
a different method and independent data sets to demonstrate
biological differences in the gene clusters we identified.
Spontaneous Loss of DNA Methylation at the Identified
Genomic Regions Is Associated with Cell Death
DKO1 cells have highly impaired DNA methyltransferase
machinery due to the absence of DNMT3B, very low protein
levels of DNMT3A, and low levels of a truncated DNMT1 (Egger
et al., 2006; Sharma et al., 2011). As a consequence of the
impaired DNA methyltransferase machinery, the global DNA
methylation level in this cell line is very low, with most of the
genes that were methylated in the parental HCT116 cells losing
this methylation in DKO1 cells. Therefore, we hypothesize that
DKO1 cells would be under a constant selective pressure to
maintain the residual DNA methylation at key regions necessary
for this cancer cell to survive.Cancer Cell 21, 655–667, May 15, 2012 ª2012 Elsevier Inc. 659
Figure 3. Validation of CpG Sites Identified with Cancer-Specific DNAMethylation Using Independent Data Sets and Association with Gene
Repression
(A) Volcano plot of the CpG loci identified as cancer-specifically methylated in colon adenocarcinoma (normal n = 16, cancer n = 168) from TCGAData Portal. The
b value difference in DNA methylation between the tumor samples and the correspondent normal samples is plotted on the x axis, and the p value for a FDR-
corrected Wilcoxon rank sum test of differences between the tumor and correspondent normal samples (13 log10 scale) is plotted on the y axis. Probes that
are significantly hypermethylated (FDR adjusted p < 0.05) in tumors are shown in red.
(B) Volcano plot gene expression data of cancer-specific DNA-methylated genes. Gene expression data were obtained from GEO (GSE 8671) from primary
normal colon (n = 32) and primary colon cancer (n = 25). For the volcano plots, gene expression fold change between the normal tissues and the tumor tissues is
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DNA Methylation DriversWe next investigated whether DKO1 cells exhibit a higher
basal level of cell death than HCT116 wild-type cells. When
quantifying cell death by measuring the externalization of
phosphatidylserine (PS) using annexin V by flow cytometry, we
observed at least four times more spontaneous cell death
in DKO1 than in the parental HCT116 cells (Figure 4A). This
suggests that DKO1 cells are indeed under constant selective
pressure, probably because during cell division, some daughter
cells lose DNA methylation at key regions due to the impaired
DNA methyltransferase activity in DKO1 cells (Egger et al.,
2006; Spada et al., 2007), and consequently, they cannot survive.
We took advantage of the increased rates of spontaneous
cell death in DKO1 cells to further test our hypothesis that
cancer cells depend on constant DNA methylation of these
regions in order to survive. Using cell sorting, we first separated
DKO1 cells into two populations: annexin V positive (early spon-
taneous apoptosis), and annexin V negative (viable cells) (Fig-
ure 4A). These two populations have distinct morphologies,
with annexin V-positive cells in the range of lower Forward
Scatter (FSC) and higher Side Scatter (SSC), a characteristic
feature of apoptotic cells (Darzynkiewicz et al., 1992), compared
to annexin V-negative cells (Figure 4B).
We then compared the DNA methylation levels of EYA4 and
IRAK3 gene promoter regions in early apoptotic and viable cells.
We have previously defined these genes as harboring cancer-
specific DNA methylation and differential expression in cancer
versus normal cells. Furthermore, these genes were in the top
tier for significantly hypermethylated genes, and for gene repres-
sion, in colon and lung adenocarcinoma. In addition we also
compared the DNA methylation levels of SYCP3 and ADAM2
gene promoter regions between early apoptotic and viable cells.
These genes were identified as having somatic cell-specific DNA
methylation and differential gene expression between somatic
and germ cells (data not shown). In agreement with our hypoth-
esis that DNA methylation-induced silencing of these regions is
required for survival, early apoptotic cells showed at least
a 27% reduction in DNA methylation in all four regions analyzed,
with some specific CpG sites having as much as 80% reduction
in DNA methylation (Figures 4C and S2A). Because degradation
of cellular mRNA is an early apoptosis-induced event (Del Prete
et al., 2002), we could not reliably measure whether this deme-
thylation was associated with re-expression of these genes in
the dying cells. In contrast, DNA degradation is a late apoptotic
event, which allowed us to study the DNA methylation status
during the first steps of apoptosis.plotted on the x axis, and the p value for a FDR-corrected t test of differences betw
Probes that are significantly (p < 0.05) downregulated in tumor tissues are show
(C) Volcano plot of the CpG loci identified as cancer-specifically methylated in
The b value difference in DNA methylation between the tumor samples and the
a FDR-correctedWilcoxon rank sum test of differences between the tumor and co
that are significantly hypermethylated (FDR adjusted p < 0.05) in tumors are sho
(D) Volcano plot gene expression data of cancer-specific DNA-methylated gen
lung adenocarcinoma (n = 27) and primary lung (n = 30). For the volcano plots, ge
plotted on the x axis, and the p value for a FDR-corrected t test of differences betw
Probes that are significantly (p < 0.05) downregulated in tumor tissues are show
(E) Venn diagram showing the overlap between the genes statistically hyperme
adenocarcinoma (n = 33; FDR adjusted p < 0.05).
(F) Venn diagram showing the overlap between the genes statistically repressed
carcinoma (n = 25; FDR adjusted p < 0.05).An alternative hypothesis is that global demethylation in
DKO1 cells, due to impaired DNA methyltransferase activity,
leads to genomic instability and cell death. To test this hypoth-
esis, we measured the global DNA methylation levels of the
early spontaneous apoptotic and viable cells and did not find
a global reduction in DNA methylation (Figure S2B), further sug-
gesting that demethylation of these specific genes lead to cell
death. In addition to test whether apoptosis itself could cause
demethylation of these regions, we treated HCT116 cells with
0.2 mM of Staurosporine (STS), a drug known to induce cell
death by blocking protein kinases (Manns et al., 2011). Next,
we sorted viable and STS-induced dead cells and did not
observe any difference in DNA methylation of these candidate
regions (Figure S2C). Altogether, this strongly suggests that
demethylation of these regions is causing cell death rather
than the other way around.
These data, together with our previous data showing that
DKO1 cells have reduced cell viability when this low level of
DNMT1, and consequently the DNA methylation level, is further
reduced by RNAi (Egger et al., 2006; Spada et al., 2007), and
that complete knockout of the maintenance DNMT1 leads to
massive cell death (Chen et al., 2007), demonstrate that these
cells are under constant selective pressure to retain DNA
methylation at these key regions that we identified here in order
to survive.
Functional Validation
We sought to further demonstrate that re-expression of genes
whose DNA methylation is critical for cancer cell survival leads
to increased cell death. We cloned the cDNA of six genes from
the cancer cluster (IRAK3, P2RY14, CDO1, BCHE, ESX1, and
ARMCX1), two from the somatic cluster (ADAM2 and SYCP3),
and one from the cell line cluster (STEAP4) into the pLJM1 lenti-
viral vector to individually reexpress these genes in HCT116
and RKO colon carcinoma cell lines (Figures S3A and S3B).
We observed that expression of each of these genes decreased
cell viability in both HCT116 and RKO cells (Figures 5A and 5B).
We also re-expressed NOX4 as a control gene (Figures 5A and
5B). NOX4 was heavily methylated in HCT116 (b value of 0.95)
and completely demethylated in DKO1 (b value of 0.007), sug-
gesting that DNA methylation-mediated repression of this gene
is not necessary for DKO1 survival. It is important to note that
these ten genes have a low relative expression in RKO (Fig-
ure S3B) and a very high basal DNA methylation level in this
cell line (Figure S3E).een the normal and the tumor tissues (13 log10 scale) is plotted on the y axis.
n in red.
lung adenocarcinoma (normal n = 4, cancer n = 19) from TCGA Data Portal.
correspondent normal samples is plotted on the x axis, and the p value for
rrespondent normal samples (13 log10 scale) is plotted on the y axis. Probes
wn in red.
es. Gene expression data were obtained from GEO (GSE7670) from primary
ne expression fold change between the normal tissues and the tumor tissues is
een the normal and the tumor tissues (13 log10 scale) is plotted on the y axis.
n in red.
thylated in colon adenocarcinoma (n = 50; FDR adjusted p < 0.05) and lung
in colon adenocarcinoma (n = 44; FDR adjusted p < 0.05) and lung adeno-
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Figure 4. Apoptosis Analysis of HCT116 and DKO1 Cells
(A) HCT116 wild-type and HCT116 DKO1 cells were stained with annexin V-FITC and PI and analyzed by FACS, showing an increased level of basal apoptotic cell
death in the HCT116 DKO1 cell line compared to HCT116 wild-type. HCT116 DKO1 cells were then sorted in viable (annexin V and PI negative) and early
apoptosis (annexin V positive and PI negative).
(B) Themorphology of viable DKO1 and early apoptosis is clearly distinct. The apoptotic cells (blue) show a characteristic phenotype of higher SSC and lower FSC
than the viable cells (red).
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DNA Methylation DriversTo gain more detailed information of how cancer cells
become dependent on DNA methylation of these genes, we
investigated how the silencing of one candidate, interleukin-1
receptor-associated kinase 3 (IRAK3), affects cancer cell
survival in more detail. IRAK3 has a cancer-specific DNA
methylation pattern, a reduced expression in colon adenocarci-
noma compared to normal colon, and a decreased DNA
methylation in spontaneously dying DKO1 cells when compared
to viable DKO1 cells. In addition, IRAK3 was a promising
candidate because, through IRAK1 (Kobayashi et al., 2002), it
indirectly inhibits three essentials pathways that cancer cells
rely on to survive: STAT3, NFkB, and MAPK (Figure S3F) (Ngo
et al., 2011; Su et al., 2009; Turnis et al., 2010). These pathways,
in turn, regulate the expression of the antiapoptotic gene
SURVIVIN (Jiang et al., 2011; Zhou et al., 2009). Consistent
with our hypothesis, using the Oncomine platform (http://
www.oncomine.org), we found reduced IRAK3 expression in
several types of cancer when compared to normal tissue
(Figure 5C) including colon adenocarcinoma when compared
to normal colon (Student’s t test p = 6.59E-4, top 15% under-
expressed gene rank) (Kaiser et al., 2007), in lung adenocarci-
noma when compared to normal lung (Student’s t test p =
5.70E-7, top 6% underexpressed gene rank) (Su et al., 2007),
in prostate carcinoma when compared to normal prostate
(Student’s t test p = 4.01E-5, top 3% underexpressed gene
rank) (Welsh et al., 2001), and in cutaneous melanoma when
compared to normal skin (Student’s t test p = 3.74E-8, top
3% underexpressed gene rank) (Talantov et al., 2005) (Fig-
ure 5C). The consistently reduced expression level of IRAK3
in a variety of cancers suggests that its silencing plays a role
in the tumorigenic process. In addition the downregulation
of IRAK3 was correlated with a statistically significant upregula-
tion of IRAK1 and SURVIVIN in the same studies (Figures S3C
and S3D).
To formally test whether the decreased expression of IRAK3
was directly responsible for the increased expression of
SURVIVIN and, consequently, increased cell survival, we re-
expressed IRAK3 in HCT116 cells. Re-expression of IRAK3
caused a striking reduction in Survivin protein levels (Figure 5D)
and caused a significant increase in cell death (Student’s t test
p = 0.0219; Figure 5E) and decrease in cell viability (p < 0.0001
Figure 5E), confirming that cancer cells require DNA methyla-
tion-induced silencing of IRAK3, and thus become dependent
on the aberrant DNA methylation. Moreover, we sought to
determine whether the silencing of IRAK3 has any effect in a
nontransformed cell. We performed a colony formation assay
in a nontumorigenic cell line, UROTSA, infected with IRAK3
shRNA or a scrambled shRNA (Figure 5F). We observed that
IRAK3 knockdown was sufficient to induce a striking increase
in colony formation (Figure 5F), thus demonstrating that the
criteria we used were successful to identify functionally relevant
genes and demonstrate that cancer cells become addicted to
their epigenetic silencing.(C) Bisulfite-sequencing analysis of CpG methylation status of four regions, from c
specific DNAmethylation cluster (SYCP3 and ADAM2). Themean percent methyla
line represents the region analyzed.
See also Figure S2.DISCUSSION
Several genome-wide studies have revealed that a large number
of promoter regions become de novo methylated in cancer
(Noushmehr et al., 2010; Portela and Esteller, 2010). However,
defining the specific ‘‘driver’’ gene regions that cancer cells
depend on for survival has proven extremely difficult (Kalari
and Pfeifer, 2010). In this study we have defined the gene
promoters whose DNA methylation is required for survival of
somatic cancer cells in culture. This group of genes could be
further subdivided into at least three subgroups: those neces-
sary to be methylated for the survival of (1) somatic cells, (2)
cancer cells, and (3) cells in culture. These sets of genes retain
DNA hypermethylation even after strong depletion of DNA
methyltransferase activity, suggesting that DNA methylation is
the main epigenetic mechanism used to maintain silencing
because these cells do not seem able to switch to other repres-
sion mechanisms such as histone modifications alone.
Genes with germline-specific expression need to be tightly
regulated in somatic tissues because their aberrant expression
could be lethal for somatic cells. For example the gene ‘‘Stil,’’
in Drosophila, is only expressed in germ cells and is necessary
for germ cell survival. When ‘‘Stil’’ is transiently expressed in
somatic tissues, it results in lethality (Sahut-Barnola and Pauli,
1999). The genes we identified in the somatic-specific DNA
methylation group are mainly germ cell-specific genes, and their
demethylation and resulting re-expression in somatic cells can
trigger apoptosis, as we showed for SYCP3 and ADAM2. This
suggests a primary role for DNA methylation as a mechanism
for repression of testes-specific genes in somatic cells (which
includes cancer cells). It also lends confidence to our analysis
because it is known that several CpG island genes are normally
DNA methylated in somatic tissue and unmethylated in germ
cells (Shen et al., 2007).
Intriguingly, none of the genes identified in the cancer-specific
group, whose DNA methylation is necessary for the survival of
cancer cells, is classically known TSGs. This suggests that
the genes we identified here are previously unknown tumor
suppressors whose silencing is necessary for cancer cell
survival. Interestingly, this group encompasses several cell
signaling molecules, such as those with nucleotide receptor
activity and G protein-coupled receptors (GPCRs). GPCRs
have recently been described to be significantly mutated in
several kinds of cancer and were found as a top category in
a systematic search for TSGs by exome and transcriptome
sequencing (Kan et al., 2010; Zhao et al., 2010). Taken together,
these results indicate amore significant role of GPCRs, as TSGs,
in cancer than previously thought.
TSGs can be silenced in cancer cells by several epigenetic
mechanisms including DNA methylation, histone modifications,
and nucleosome positioning (Jones and Baylin, 2007). It is also
known that cancer cells depend on the silencing of TSGs and,
consequently, are hypersensitive to the re-expression of theseancer-specific methylated cluster (EYA4 and IRAK3) and from somatic tissue-
tion at each CpG site is derived from clones shown on Figure S2A. The capped
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Figure 5. Functional Validations
(A) Overexpression of nine candidate genes from the cancer cluster (P2RY14, IRAK3,CDO1, ESX1, ARMCX1, BCHE), somatic cluster (SYCP3 and ADAM2), and
cell culture cluster (STEAP4). Shown is the fraction of Empty-Vector at the indicated times, normalized to the day 0 values. NOX4 was used as a control gene
because it is hypermethylated in HCT116 cells and completely demethylated in DKO1 cells. Data represent the mean ± SEM.
(B) Overexpression of the same nine candidate genes reduces viability of RKO cancer cells. Shown is the fraction of Empty-Vector at the indicated times,
normalized to the day 0 values. NOX4 was used as a control gene. Data represent the mean ± SEM.
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Xue et al., 2007). We propose here that because of this TSG
hypersensitivity, and because some of these key TSGs are
silenced by epigenetic mechanisms, cancer cells become
addicted to this aberrant epigenetic silencing.
Indeed, we demonstrated that re-expression of the genes we
identified here decreases cell viability, highlighting the need for
their constant repression. Furthermore, we showed that one of
these genes, IRAK3, negatively regulates expression of the
antiapoptotic gene SURVIVIN. It was recently shown that
oncogenic activation of MYD88 led to IRAK1 phosphorylation
and, consequently, NFkB activation, promoting cell survival
(Ngo et al., 2011). IRAK3 is a negative regulator of this signaling
pathway, inhibiting IRAK1 phosphorylation (Janssens and
Beyaert, 2003), thus supporting our findings and suggesting
a tumor suppressor role for IRAK3. IRAK3 was also previously
identified, in an RNAi-based genetic screen, as able to suppress
transformation of human mammary epithelial cells (Westbrook
et al., 2005), consistent with our finding that IRAK3 knockdown
in nontumorigenic cells increased colony formation and suggest-
ing that the genes found in this cancer group are excellent
targets for therapy. In addition because these genes depend
on DNA methylation-mediated gene silencing, these may be
especially good targets for epigenetic therapy (Kelly et al., 2010).
It has been known for many years that de novo DNA methyla-
tion occurs during the cell-culturing process (Antequera et al.,
1990; Jones et al., 1990; Wilson and Jones, 1983). Here, we
identified a group of genes whose silencing by DNA methylation
is required for cells to survive in culture. This group of genes was
highly methylated in colon, bladder, and breast cell lines and
unmethylated in primary-matched tissue analyzed, independent
of the tumorigenic state (data not shown). Intriguingly, this group
encompasses many nucleosome assembly genes, including
several histone variants about which little is known. These results
suggest that during the cell-culturing process, extensive
changes in expression of nucleosome constituents are neces-
sary for cell survival. It also highlights the importance of careful
interpretation of epigenetic results obtained from cell culture
experiments.
Taken together, by identifying the minimal DNA methylation
profile necessary for the survival of cancer cells and comparing
this profile in several primary normal tissues and cancer types,
we were able to find, and experimentally validate, a group of
genes whose de novo methylation in cancer is functionally
relevant for the survival of cancer cells. We also found that,
despite the complex nature of tumorigenesis, cancer cells(C) Metaanalysis using the Oncomine (http://www.oncomine.org) for IRAK3 expre
on data sets performed in colon adenocarcinoma (Kaiser et al., 2007), lung ad
cutaneous melanoma (Talantov et al., 2005). The y axis represents log2 medi
interquartile range (25th–75th percentile). Whiskers represent the 10th–90th perce
(D) Overexpression of IRAK3 in HCT116 cells induces a reduction in the Survivin l
pLJM1 empty vector (E/V) or pLJM1-IRAK3. Histone H3 was used as a loading c
(E) IRAK3 expression induces cell death of cancer cells. HCT116 infected with pLJ
analyzed by FACS, showing an increased level of cell death in the cell overexpre
showed a reduced cell number in culture than HCT116 empty vector (lower pane
(F) IRAK3 knockdown induces colony formation in a nontumorigenic cell. UROT
activity than UROTSA infected with a scrambled shRNA.Western blot analysis of I
was performed. Actin was used as a loading control.
See also Figure S3.become dependent on the DNA methylation-mediated epige-
netic silencing of these genes. These driver epigenetic events
associated with cancer cell survival are potentially good candi-
dates for the development of new, target-specific, therapies.
EXPERIMENTAL PROCEDURES
Cell Lines, DNA and RNA Preparations, Antibodies, and Primers
These are described in the Supplemental Experimental Procedures.
DNA Methylation Assay
Genomic DNA samples (1 mg each) were bisulfite converted using the Zymo
EZ DNA methylation kit (Zymo Research, Orange, CA, USA; catalog #D5002)
according to the manufacturer’s instructions. Bisulfite-converted DNA was
eluted in an 18 ml vol, and 3 ml was removed for post-bisulfite quality control
tests as described previously by Campan et al. (2009). All cell lines and
clinical samples passed bisulfite conversion quality control and were
subsequently processed for the Illumina Infinium DNA methylation platform
(HumanMethylation27 BeadChip). A b value of 0–1.0 was reported for each
CpG site (methylation from 0% to 100%, respectively). b Values were calcu-
lated as described previously by Wolff et al. (2010).
The Infinium methylation assays were performed by the USC Epigenome
Center in accordancewith themanufacturer’s instructions. The assay informa-
tion is available at http://www.illumina.com. Heat maps were generated for
the b values. All the DNA methylation data from primary tissue was obtained
from TCGA (http://cancergenome.nih.gov/).
To analyze the DNA methylation status of individual DNA molecules, we
cloned bisulfite-converted PCR fragments into the pCR2.1 vector using the
TOPO-TA cloning kit (Invitrogen, Carlsbad, CA, USA). Individual colonies
were screened for the insert, and the region of interest was sequenced using
M13 primers as previously described by Wolff et al. (2010).
H3K27me3 Status in ESCs as a Predictive Method for DNA
Methylation in Cancer
H3K27me3 profile in H9 ESCs was obtained from previously published data by
Lee et al. (2006). Next, we intersected the genomic position of the Infinium
probes with the H3K27me3 status in H9 ESCs to define which probes are
H3K27me3 positive and which are H3K27me3 negative in ESCs. From the
approximately 24,000 probes used in Figure 1, we found approximately
7.7% as H3K27me3 positive in ESCs and 79.7% as H3K27me3 negative in
ESCs, and we could not determine the H3K27me3 status in ESCs of 12.6%
of the probes.
Genomic Architecture as a Predictive Method for DNA Methylation
in Cancer
We used previously published data from Este´cio et al. (2010) that predict the
inherent susceptibility to DNA methylation in cancer based on SINE and
LINE retrotransposon density in a 20 kb window around the TSS of each
gene. Briefly, they calculate the log odds ratio of SINE and LINE retrotranspo-
sons per 1 kb window, and the sum of log odds scores in the 20 kb region
allowed the classification of each gene as methylation prone, methylation
intermediate, and methylation resistant.ssion. Box plots showing decreased expression of IRAK3 during tumorigenesis
enocarcinoma (Su et al., 2007), prostate carcinoma (Welsh et al., 2001), and
an-centered intensity (normalized expression). Shaded boxes represent the
ntile. The bars denote the median.
evels. Western blot analyses of IRAK3 and Survivin after lentiviral infection with
ontrol.
M1 empty vector or pLJM1 IRAK3was stained with annexin V-FITC and PI and
ssing IRAK3 (upper panel). Re-expression of IRAK3 in HCT116 wild-type cells
l). *p < 0.05, ***p < 0.0001. Data represent the mean ± SEM.
SA infected with a shRNA against IRAK3 presented a higher colony formation
RAK3 after lentiviral infection with shRNA against IRAK3 or a scrambled shRNA
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Cellular apoptosis wasmeasured by annexin V and propidium iodide (PI) stain-
ing using annexin V-FITC Apoptosis Detection Kit (MBL), according to the
manufacturer’s protocol. Following staining the cells were analyzed and sorted
by FACS analysis as described previously by De Carvalho et al. (2011).
Gene Expression Analysis
All gene expression data from primary tissue were obtained from GEO
(GSE8671 and GSE7670). The data were median normalized and log2
transformed.
Ectopic Gene Expression
This is described in the Supplemental Experimental Procedures.
Statistical Analysis
This is described in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
Infinium methylation data were deposited in NCBI’s Gene Expression
Omnibus: series accession number GSE36534.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2012.03.045.
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